Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 26279761/?report=reader!4532750!26279761     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Transl+Res 2015 ; 7 (6): 1181-8 Nephropedia Template TP {{tp|p=26279761|t=2015. CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma |pdf=|usr=}}{{26279761}} gab.com Text CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma JO: Am J Transl Res http://www.kidney.de/pget.php?&tw=1&pmid=26279761 #FOAvip Soft tissue sarcoma (STS) is a heterogenous tumor arising from the embryonic mesoderm represented by approximately 50 histological subtypes. Effective therapeutic intervention is lacking for recurrent, late stage and metastatic disease. CD39, a cell-surface ectonucleotidase, has previously been shown to be upregulated in hematological malignancies and various epithelial tumors, but not in STS. Here, we show by mass spectrometry and immunohistochemistry that CD39 is highly expressed in primary patient sarcoma samples. Moreover, CD39 nucleotidase activity is enhanced in fibrosarcoma compared with normal control cells. We demonstrate that an inhibitory monoclonal anti-CD39 antibody, abrogates CD39 enzymatic activity significantly and prolongs survival in a lethal metastatic patient-derived sarcoma model. Taken together, the data suggest CD39 is a novel therapeutic target for the treatment of STS. Twit Text FOAVip CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma ????Am J Transl Res http://www.kidney.de/pget.php?&tw=1&pmid=26279761 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26279761 #FOAvip English Wikipedia <ref>{{Cite pmid|26279761}}</ref> CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma #MMPMID26279761 Hayes GM; Cairns B; Levashova Z; Chinn L; Perez M; Theunissen JW; Liao-Chan S; Bermudez A; Flory MR; Schweighofer KJ; H van der Horst E Am J Transl Res 2015[]; 7 (6): 1181-8 PMID26279761show ga Soft tissue sarcoma (STS) is a heterogenous tumor arising from the embryonic mesoderm represented by approximately 50 histological subtypes. Effective therapeutic intervention is lacking for recurrent, late stage and metastatic disease. CD39, a cell-surface ectonucleotidase, has previously been shown to be upregulated in hematological malignancies and various epithelial tumors, but not in STS. Here, we show by mass spectrometry and immunohistochemistry that CD39 is highly expressed in primary patient sarcoma samples. Moreover, CD39 nucleotidase activity is enhanced in fibrosarcoma compared with normal control cells. We demonstrate that an inhibitory monoclonal anti-CD39 antibody, abrogates CD39 enzymatic activity significantly and prolongs survival in a lethal metastatic patient-derived sarcoma model. Taken together, the data suggest CD39 is a novel therapeutic target for the treatment of STS. äCD39 is a promising therapeutic antibody target for the treatment of s(epmc).pdf DeepDyve Pubget Overpricing